Event report: Individual Shareholders’ Meeting held on October 23, 2014

October 30, 2014 - Paris (France) - Cellectis (Alternext: ALCLS.PA), a biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CART cells (UCART), hosted a meeting for individual shareholders at its head office on October 23, 2014.

Approximately 50 people attended this meeting during which André Choulika, Chairman and Chief Executive Officer of Cellectis, Mathieu Simon, Executive Vice-President in charge of Operations, Luc Mathis, Chief Executive Officer of Cellectis plant sciences, and Thierry Moulin, Chief Financial Officer, gave presentations on the Company and, in particular, its therapeutic programs under development, the Cellectis plant sciences business, and its first-half 2014 financial results to June 30, 2014.

Summary of the event

• Cellectis overview

André Choulika discussed Cellectis’ expertise in the field of genome engineering, its portfolio of patents, and two large-scale collaboration agreements with Pfizer and Servier. Today, the Cellectis pipeline includes 33 oncology targets (12 for Cellectis, 6 for Servier, and 15 for Pfizer), of which one key product candidate, UCART19, is in partnership with Servier. Phase I trial of UCART19 is expected to start in the 3rd quarter of 2015. André Choulika also explained the multichain CAR that Cellectis has been developing. This is a new generation of CAR, which is expected to increase engineering possibilities and which represents potential progress in targeting solid tumors.

• Cellectis therapeutic programs

Mathieu Simon presented the first two product candidates developed from T-cells by Cellectis: UCART19 (in partnership with Servier) and UCART123, both products stemming from the Company’s proprietary platform of adoptive immunotherapy against cancer. The Company believes this platform can be implemented on a large scale for different therapeutic indications in oncology. Dr. Simon described Cellectis’ manufacturing process and explained the strategy employed with regard to regulatory constraints applicable to CART cells in adoptive immunotherapy. Dr. Simon also explained Cellectis’ scientific and technological strategy.

• Cellectis plant sciences

Luc Mathis presented Cellectis plant sciences, whose core business is to develop innovative agricultural products, concentrated on large-scale markets such as potato, soybean, wheat or even canola, based on its proprietary platform which aims to increase agronomic value and agricultural quality for the agro-food business.

• Half-year 2014 financial results

Thierry Moulin discussed recent changes in the Company, which has strategically refocused its activities on oncology and plant science. This refocusing has resulted in a simplified structure and in enhanced control over costs and expenses. The Company had 103 million euros of cash and cash equivalents as of September 30, 2014. Mr. Moulin also gave details of the development of the Company’s shareholding, explaining that the interests of foreign shareholders (principally in the United States and the United Kingdom) increased from 15.3% in May 2013 to 42.3% in August 2014.

• Questions and answers

This meeting was also an opportunity to discuss recent strategic changes in the Company. For example, Dr. Choulika explained that the microalgae program had been abandoned because the development times proved to be much too long. In addition, André Choulika explained that the operational implementation of Scéil’s offer had been delayed owing to the withdrawal of the partner laboratory in Singapore. The offer had been relaunched in September 2014.

André Choulika and the entire management team of Cellectis thanked the shareholders present at this meeting for their interest, for their loyalty and for the quality of discussion during the presentations.